Join the club for FREE to access the whole archive and other member benefits.

Cleara Biotech

Cleara is developing therapeutics to eliminate senescent cells.

Cleara Biotech discovered a mechanism that shows how senescent cells escape the natural elimination process. Based on this discovery, Cleara is developing therapeutics to treat patients with a range of diseases caused by this failure to clear senescent cells.

Visit website: https://www.clearabiotech.com/

 cleara-biotech

 ClearaBiotech

People at Cleara Biotech

Peter de Keizer

Associate Professor at UMC Utrecht, Founder and Managing Director at Cleara Biotech

Cleara Biotech News

$2.5M seed financing round closed by Cleara Biotech-targets cellular senescence

Longevity Technology - 03-Oct-2022

Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells

Read more...

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play

Read more...

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...

Read more...

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed

Read more...

LEAF report from the Longevity Leaders Conference

Lifespan.io (LEAF) - 06-Feb-2019

Encouraging signs from big companies - more interviews to follow

Read more...

Cleara Biotech Joins the Race to Develop Senolytic Therapies

Lifespan.io (LEAF) - 09-Jul-2018

This therapy uses a modified FOXO4 to promote apoptosis in senescent cells

Read more...